PT989131E - Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais - Google Patents

Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais

Info

Publication number
PT989131E
PT989131E PT97934774T PT97934774T PT989131E PT 989131 E PT989131 E PT 989131E PT 97934774 T PT97934774 T PT 97934774T PT 97934774 T PT97934774 T PT 97934774T PT 989131 E PT989131 E PT 989131E
Authority
PT
Portugal
Prior art keywords
compound
inventive compound
useful
pharmaceutically acceptable
compounds
Prior art date
Application number
PT97934774T
Other languages
English (en)
Inventor
Syuji Ehara
Hiroyuki Yoshitomi Sueoka
Hirotsugu Komatsu
Haruhito Kobayashi
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of PT989131E publication Critical patent/PT989131E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT97934774T 1996-09-13 1997-08-11 Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais PT989131E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24379396 1996-09-13

Publications (1)

Publication Number Publication Date
PT989131E true PT989131E (pt) 2003-03-31

Family

ID=17109041

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97934774T PT989131E (pt) 1996-09-13 1997-08-11 Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais

Country Status (14)

Country Link
EP (1) EP0989131B1 (pt)
JP (1) JP3094453B2 (pt)
KR (1) KR100338144B1 (pt)
CN (1) CN1109037C (pt)
AT (1) ATE227727T1 (pt)
AU (1) AU716490B2 (pt)
CA (1) CA2265645C (pt)
DE (1) DE69717160T2 (pt)
DK (1) DK0989131T3 (pt)
EA (1) EA001732B1 (pt)
ES (1) ES2182108T3 (pt)
NO (1) NO323892B1 (pt)
PT (1) PT989131E (pt)
WO (1) WO1998011111A1 (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
EP1887008B1 (en) * 2005-05-30 2021-04-21 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
RS54645B1 (sr) 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
JP6215315B2 (ja) 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
MX2014015986A (es) * 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
WO2014026997A1 (de) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepine
CN104781259B (zh) 2012-09-28 2018-06-01 拜耳制药股份公司 抑制bet蛋白的5-芳基三唑并氮杂*
CN104968334B (zh) * 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015014998A1 (en) * 2013-08-01 2015-02-05 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
CN103694253A (zh) * 2013-11-04 2014-04-02 湖南华腾制药有限公司 一种噻吩并三唑并[4,3-a][1,4]二氮杂卓类化合物的制备方法
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
BR112016017045A2 (pt) 2014-01-31 2017-08-08 Dana Farber Cancer Inst Inc Derivados de diazepano e usos dos mesmos
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
EP3416969B1 (en) 2016-02-15 2021-05-05 The Regents of The University of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
MX384905B (es) 2016-04-12 2025-03-14 Univ Michigan Regents Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
EP3512855B1 (en) 2016-09-13 2022-07-27 The Regents of the University of Michigan Fused 1,4-oxazepines as bet protein degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
KR20190092429A (ko) 2016-12-16 2019-08-07 에프. 호프만-라 로슈 아게 다이아제핀 유도체의 제조 방법
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CN110914280B (zh) * 2017-05-31 2024-05-03 阿尤米制药公司 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂䓬衍生物
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.
TW202019946A (zh) 2018-07-04 2020-06-01 日商田邊三菱製藥股份有限公司 具有ｂｅｔ蛋白質分解誘導作用的醯胺化合物及其作為醫藥的用途
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
JP7292400B2 (ja) * 2019-03-07 2023-06-16 メッドシャイン ディスカバリー インコーポレイテッド ＢＥＴ Ｂｒｏｍｏｄｏｍａｉｎタンパク質の阻害とＰＤ－Ｌ１遺伝子の調節の両方の効果を持つ化合物
AU2021215623A1 (en) 2020-02-06 2022-08-25 Mitsubishi Tanabe Pharma Corporation Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof
WO2022048685A1 (zh) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 苯并四氢呋喃肟类化合物的晶型及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE870123L (en) * 1986-01-21 1987-07-21 Boehringer Ingelheim Int Thieno-1,4-diazepines
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
YU133090A (sh) * 1989-07-12 1993-10-20 Boehringer Ingelheim Kg. Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
WO1994006801A1 (fr) * 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation comme medicament
DE4027470A1 (de) * 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
DE69230891T2 (de) * 1991-12-11 2000-10-05 Yoshitomi Pharmaceutical Industries, Ltd. Arzneimittel zur Behandlung von Autoimmunerkrankungen
JP3215489B2 (ja) * 1992-04-23 2001-10-09 日本電信電話株式会社 燃料電池排熱利用システムとその制御方法
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
CA2159344A1 (en) * 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
JP3633008B2 (ja) * 1993-11-15 2005-03-30 三菱ウェルファーマ株式会社 チエノトリアゾロジアゼピン化合物
JPH0879471A (ja) * 1994-09-01 1996-03-22 Konica Corp 画像形成装置

Also Published As

Publication number Publication date
DK0989131T3 (da) 2003-03-03
DE69717160T2 (de) 2003-05-08
WO1998011111A1 (en) 1998-03-19
JP3094453B2 (ja) 2000-10-03
EA199900287A1 (ru) 1999-08-26
KR100338144B1 (ko) 2002-05-24
CA2265645A1 (en) 1998-03-19
EP0989131B1 (en) 2002-11-13
EP0989131A4 (en) 2000-03-29
NO323892B1 (no) 2007-07-16
CN1237180A (zh) 1999-12-01
NO991191D0 (no) 1999-03-11
CA2265645C (en) 2007-01-23
HK1023571A1 (en) 2000-09-15
AU716490B2 (en) 2000-02-24
NO991191L (no) 1999-04-23
ATE227727T1 (de) 2002-11-15
CN1109037C (zh) 2003-05-21
DE69717160D1 (de) 2002-12-19
EA001732B1 (ru) 2001-08-27
ES2182108T3 (es) 2003-03-01
EP0989131A1 (en) 2000-03-29
AU3786097A (en) 1998-04-02
KR20000036057A (ko) 2000-06-26

Similar Documents

Publication Publication Date Title
PT989131E (pt) Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais
ATE232531T1 (de) Heterobizyklische derivate
LU90014I2 (fr) Invirase ou un de ses dérivés ou sels pharmaceutiquement acceptables Saquinavir
AU8531101A (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
SE9901573D0 (sv) New compounds
ZA895256B (en) Use of polymeric compounds in treatment
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
FI102964B1 (fi) Terapeuttisia yhdisteitä
NO923200D0 (no) Piperidin-derivater
ATE161531T1 (de) Acridine-1,8-dionderivate als therapeutisches mittel
GR3019917T3 (en) Benzimidazole derivatives as antimicrobal agent against campylobacter pylon
NO905620D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
SE9901572D0 (sv) New compounds
KR970703147A (ko) 동맥경화 억제제(Arteriosclerosis Depressant)
DK0876144T3 (da) Terapeutiske anti-astmamidler indeholdende organiske selenforbindelser
SE0103272D0 (sv) Chemical compounds
RU94022757A (ru) Агент торможения агрегации тромбоцитов
ATE109003T1 (de) Therapeutisches mittel gegen pollakiurie, harndrang oder harninkontinenz, das alpha-phenyl- alpha-pyridylalkan-carbonsäurederivate enthält.
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
GR3030952T3 (en) Salmycins, a process for their preparation and their use as a pharmaceutical.
EP0274230A3 (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
GB8709546D0 (en) Pharmaceutical use of organic compounds
IT1107771B (it) Composizione farmaceutica antiartritica ed antiinfiammatoria